-
Nuvectis Pharma NasdaqCM:NVCT Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Location: 1 Bridge Plaza, Fort Lee, NJ, 07024, United States | Website: https://www.nuvectis.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
191.1M
Cash
29.86M
Avg Qtr Burn
-3.016M
Short % of Float
16.23%
Insider Ownership
46.53%
Institutional Own.
9.93%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NXP800 Details Ovarian cancer (ARID1a), Cancer | Phase 1b Update | |
NXP900 Details YES1-amplified Non-small cell lung cancer | Phase 1b Initiation | |
NXP800 Details Cholangiocarcinoma | Phase 1 Data readout |